Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Dickson

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced SarcomaNicholas D Klemen, Sinchun Hwang, Martina Bradic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
Journal for Immunotherapy of Cancer|April 2, 2022
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single centerEvan Rosenbaum, Cristina R Antonescu, Shaleigh Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1CMark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Journal for Immunotherapy of Cancer|September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapyBenjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
JAMA Oncology|January 24, 2020
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical TrialCiara M Kelly, Cristina R Antonescu, Timothy Bowler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced SarcomaCiara M Kelly, Li-Xuan Qin, Karissa A Whiting, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcomaEvan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced SarcomaNicholas D Klemen, Sinchun Hwang, Martina Bradic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
Journal for Immunotherapy of Cancer|April 2, 2022
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single centerEvan Rosenbaum, Cristina R Antonescu, Shaleigh Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1CMark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Journal for Immunotherapy of Cancer|September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapyBenjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
JAMA Oncology|January 24, 2020
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical TrialCiara M Kelly, Cristina R Antonescu, Timothy Bowler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced SarcomaCiara M Kelly, Li-Xuan Qin, Karissa A Whiting, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcomaEvan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
Pageof 8